Home → News → Clinical Trials → Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

July 2009

July 7

XOMA Announces Conference Call and Webcast On July 14 to Review Top Line Multi-dose and Other Results of Its Phase 1 Clinical Trial of XOMA 052 in Type 2 Diabetes Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax CMV Vaccine Phase 2 Interim Efficacy Results Published in The Lancet...Cervarix protects against the five most common cancer-causing virus types Presse Release: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody. South Jersey Healthcare Selects MobileMD for Health Information Exchange Service Stinson Brand Innovation, Inc. Releases White Paper Trends In Pharma Branding Over The Next Five Years Denosumab Demonstrates Superiority Over Zometa in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

July 9

Revance Therapeutics Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax) for the Treatment of Inhalation Anthrax Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity Questcor Launches New Corporate Website Physicians and Pharmacists Reach for OTC Relief With New Epocrates Reference Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial

July 14

Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients Noven Reports Positive Phase 2 Results for Mesafem Non-Hormonal Therapy for Vasomotor Symptoms IP Advocate Enhances Interactive IPAO Forum with New ?Expert Opinions' Section Safety and Cognitive Stability Are Key Findings in Phase IIA Trial of New Alzheimer's Disease Treatment from Humanetics Corporation Light-directed drug delivery system slows growth of invasive tumours Oxford Biomedica Announces Update On Phase I/Ii Study Of Prosavin In Parkinson's Disease Avid Radiopharmaceuticals Phase II Results Featured in Two Presentations at Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) New Podcast in Patient Perspectives Series: Searching for a Cure EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator Study Evaluating Efficacy and Safety of Two Low-dose Regimens of Premarin Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published Endocyte to Present Data on EC145 at the IASLC 13th World Conference on Lung Cancer ParagonRx Creates New Website Featuring REMS Help Center for Pharma Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII

July 15

I-many Government Pricing Goes Live at Graceway Pharmaceuticals Targacept's TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder Abraxis BioScience Completes Enrollment of Pivotal Phase III Advanced Lung Cancer Study Evaluating ABRAXANE Vs. Taxol Oncolytics Biotech Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease At ICAD Annual Meeting Sapient Delivers New Online Multilingual Resource to Support Thousands of Families Affected by Rare Congenital Syndrome ReachMD Announces a New Radio Programming Series, ?Diabetes Discourse,? hosted by Steven V. Edelman, MD

July 16

National Survey Indicates Latinos and Blacks in America Twice as Likely as Caucasians to Be Diagnosed with Diabetes Results of Phase I and Phase IIa Clinical Studies Confirm the Inhibitory Effect of Proprietary Ipsen's BIM23A760 First-in-Class ?Chimeric? Compound on Growth Hormone, IGF-1 and Prolactin Levels1 Inovio Biomedical H1N1 Influenza DNA Vaccines Demonstrate 100% Responses Against Swine Flu in Vaccinated Pigs avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin Psoriasis Relief DRTV Campaign Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen?s BIM23A760 first-in-class ?chimeric? compound on growth hormone, IGF-1 and prolactin levels Targacept?s TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes Oncolytics Biotech Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC Former AMA Chief and Other Members of the Coalition to Protect Patients' Rights to Hold Press Conference to Discuss Health Reform

July 21

Xeloda-Oxaliplatin Combination (XELOX) Shown to Be More Effective Than Standard Chemotherapy Regimen in Adjuvant Colon Cancer Isentress (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus in Head-to-Head DURATION-3 Study 96-Week MERIT ES Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis Foresight Biotherapeutics Announces Positive Results from an Open Label Pilot Study in Patients with Viral Conjunctivitis Thermo Fisher Scientific Showcases Breadth of Clinical Chemistry Solutions at AACC 2009 Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients Isentress (raltegravir), from MSD, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy Raltegravir as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naive Patients Up to 144 Weeks When Used in Combination Therapy Orexigen Successfully Meets Phase 3 Endpoints in Obesity Trials

July 22

Takeda and Sucampo Report Top-Line Results of Two Phase 3 Trials of Lubiprostone in Opioid-Induced Bowel Dysfunction -Contrave Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- Actelion's PGI2 receptor agonist demonstrates efficacy in pulmonary arterial hypertension patients - Morbidity-Mortality Phase III study to be initiated before year-end The American Academy of Pharmaceutical Scientists (AAPS) Hires Environics Communications to Provide PR for Annual Meeting 96-Week Safety and Efficacy Findings Presented for Intelence (etravirine) As Part of HIV Combination Therapy AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine BIO Issues Call for Sessions for 2010 BIO International Convention Data Show ATryn Effectively Prevents Serious Blood Clots in Patients with Hereditary Antithrombin Deficiency FoldRx Pharmaceuticals Announces Positive Results from Pivotal Phase II/III Clinical Study of Tafamidis Siemens Showcases Innovative Products and Educational Offerings Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009 PolyMedix to Present at 5th International AIDS Society (IAS) Conference Cape Town, South Africa New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed SoCalBio's 11th Investor & Partnership Conference to Explore Post-Recession Funding Strategies for Life Science Firms New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies Merck Issues Statement on WHO Study Showing First Evidence That Elimination of River Blindness is Feasible in Africa

July 28

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma Saphris (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer's disease at ICAD 2009, Vienna, Austria NeurogesX Announces Preliminary Results of FDA-Requested Qutenza Study Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease CytRx Drug Candidate INNO-206 Results in Ovarian Tumor Shrinkage in Animal Trials Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer Biofrontera AG (DE) - Ad hoc: Clinical study with BF-derm1 shows efficacy in severe chronic urticaria Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

July 30

Obagi Medical Products Releases Results of a Clinical Trial Showing Optimized Patient Outcomes When Condition & Enhance System is Used in Combination with Botulinum Toxin Type A Obagi Medical Products Reveals Results of a Meta-Analysis Comparing the Company's Novel 5 Percent Solubilized BPO to Other Prescription 5 Percent BPO and Combination BPO/Clindamycin Topical Products Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference Child and Adolescent Psychiatry and Mental Health Publishes Vyvanse ADHD Data Cardinal Health Welcomes Record Number of Attendees at its Annual Independent Pharmacy Trade Show Teva's Forum Draws Key Pennsylvania Healthcare Leaders Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose

Clinical Trial Results Archive

2005

April

More News Resources

(web6)